Benzydamine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 29, 2026

Benzydamine

Active ingredient · 5 therapeutic classes

GB MHRA

Drug class: Other Antiinflammatory and Antirheumatic Agents, Non-Steroids
Availability: See label
Markets covered: 1
Products on record: 31

M01AXOther Antiinflammatory and Antirheumatic Agents, Non-Steroids A01ADOther Agents For Local Oral Treatment G02CCAntiinflammatory Products For Vaginal Administration M02AAAntiinflammatory Preparations, Non-Steroids For Topical Use R02AXOther Throat Preparations

Overview

Benzydamine is an active pharmaceutical ingredient in the Other Antiinflammatory and Antirheumatic Agents, Non-Steroids group (M01AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
GB United Kingdom	MHRA	31	May 29, 2026

GBUnited Kingdom· MHRA

31 products

Uses

GBOfficial regulatory label· revised May 29, 2026[1]

Benzydamine Spray is a locally acting analgesic and anti-inflammatory treatment for the throat and mouth. It is especially useful for the relief of pain in traumatic conditions such as following tonsillectomy or the use of a naso-gastric tube, dental surgery.

How to take

Sources & citations

[1]MHRA (UK) · PL113110900 · revised May 29, 2026

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 29, 2026[1]

Within each frequency grouping, undesirable effects are presented in order of the decreasing seriousness The following frequency categories are used: Very common (≥ 1/10), Common (≥ 1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), Rare (≥1/10,000 to <1/1,000) and Very rare (<1/10,000), not known (cannot be estimated from the available data).
The most common side effects are numbness and a stinging feeling in the mouth.
Respiratory, thoracic and mediastinal disorders Very rare:
Laryngospasm or bronchospasm Gastrointestinal disorders Uncommon: Oral numbness (hypoesthesia) and a stinging feeling in the mouth (oral pain). The stinging has been reported to disappear upon continuation of the of the treatment, however if it persists it is recommended that treatment be discontinued.
Skin and subcutaneous tissue disorders Very rare: pruritus, urticaria, photosensitivity reaction and a rash Frequency not known: Angioedema Immune system disorders Frequency not known: Anaphylactic reaction which can be potentially life- threatening.
Hypersensitivity reactions Methyl parahydroxybenzoate may cause allergic reactions (possibly delayed). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 29, 2026[1]

Benzydamine use is not advisable in patients with hypersensitivity to acetylsalicylic acid or other NSAIDs. Bronchospasm may be precipitated in patients suffering from or with a previous history of bronchial asthma. Caution should be exercised in these patients.
Avoid contact with the eyes. If the condition is aggravated or not improved use should cease. Contains methyl parahydroxybenzoate which may cause allergic reactions (possibly delayed) This medicine contains less than 1 mmol sodium (23 mg) per dose of 8 puffs, that is to say essentially ‘sodium-free’.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations